Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6110571 | 0.89 | DRD2 (0.45) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6111978 | 0.85 | CXCR3 (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6112043 | 0.85 | PRKAB2 (0.53) | KMT2AMCHR1DRD2DRD4 | |
| SCHEMBL1769972 | 0.84 | HTR7 (0.43) | DRD2 | |
| SCHEMBL6111246 | 0.84 | CXCR3 (0.49) | SMN1; SMN2MCHR1MAPTDRD2 | |
| SCHEMBL6111567 | 0.84 | MEN1 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6112338 | 0.84 | MLNR (0.45) | ALDH1A1SMN1; SMN2P2RY12DRD2DRD4 | |
| SCHEMBL6111569 | 0.84 | CXCR3 (0.54) | ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL6111270 | 0.83 | CXCR3 (0.51) | SMN1; SMN2MCHR1LMNAOPRM1CHRM4 | |
| SCHEMBL6111833 | 0.83 | HDAC3 (0.48) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LES LABORATOIRES SERVIER (FR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | BAX, CASP3, BCL2 | ALDH1A1 2604/4885MEN1 2752/4885KMT2A 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.